Sangamo BioSciences Announces Data from Trial of SB-728-T Shows Sustained Cut of Viral Load At or Below Detect Limit

Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today the presentation of new data from its ongoing Phase 2 clinical trial (SB-728-902 Cohort 5) to evaluate a single infusion of Sangamo's novel ZFP Therapeutic^®, SB-728-T, for the treatment of HIV/AIDS. The data demonstrate functional control of the virus at or below the limit of detection